Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Bought by Nantahala Capital Management LLC

Nantahala Capital Management LLC raised its position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 30.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,981,980 shares of the company's stock after purchasing an additional 464,284 shares during the period. Nantahala Capital Management LLC owned 7.12% of Vistagen Therapeutics worth $5,847,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. R Squared Ltd purchased a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at about $25,000. Jane Street Group LLC purchased a new stake in shares of Vistagen Therapeutics during the 3rd quarter worth approximately $59,000. Virtu Financial LLC raised its stake in shares of Vistagen Therapeutics by 30.5% during the 3rd quarter. Virtu Financial LLC now owns 20,210 shares of the company's stock worth $61,000 after buying an additional 4,722 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Vistagen Therapeutics during the 4th quarter worth $66,000. Finally, Prosperity Wealth Management Inc. acquired a new position in shares of Vistagen Therapeutics during the 4th quarter worth $86,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

Vistagen Therapeutics Stock Down 5.1 %

NASDAQ:VTGN opened at $2.22 on Monday. The company has a market capitalization of $64.07 million, a PE ratio of -1.50 and a beta of 0.56. Vistagen Therapeutics, Inc. has a 52-week low of $1.90 and a 52-week high of $4.96. The stock has a fifty day simple moving average of $2.48 and a 200-day simple moving average of $2.72.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02. The firm had revenue of $230 billion during the quarter, compared to analysts' expectations of $0.18 million. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. As a group, equities analysts anticipate that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current year.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.